ArticleAAPS PharmSciTech2025
In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) suffers from poor aqueous solubility and extensive first-pass metabolism, which significantly limits its oral bioavailability. In our earlier work, we developed camel milk-derived exosomes (CMDE) as nanocarriers to enhance CBD bioavailability, confirmed through in vivo pharmacokinetic evaluations. In this study, we further characterized the formulation by performing an in silico physiologically based pharmacokinetic (PBPK) simulation using GastroPlus™, integrating in vitro dissolution data. The simulation demonstrated that CBD absorption improved markedly with exosomal encapsulation, achieving 97.8% compared to 13.1% for free CBD. Additionally, CBD-exosomes produced an 8.66-fold increase in maximum plasma concentration (Cmax) and a 7.15-fold increase in the area under the curve (AUC), with predominant uptake observed in the duodenum and jejunum. These computational findings closely mirrored our in vivo results, providing mechanistic insights into the enhanced oral absorption of CBD via exosomal encapsulation. Furthermore, in vitro cytotoxicity studies revealed that combining CBD-CMDE with Paclitaxel (PTX) produced synergistic effects, enabling a two-fold reduction in the required PTX dose. In MDA-MB-231 DOX RT xenograft models, the combination of CBD-CMDE and PTX reduced tumor burden by 2.5-fold relative to controls. Western blot analyses indicated significant downregulation of PI3K/AKT/mTOR pathway regulators, along with modulation of immune markers, suggesting an immune-activating component. Whole-body imaging further confirmed the in vivo targetability of CMDE. This study represents the first application of PBPK modeling, based on in vitro dissolution data, to assess the pharmacokinetics of CBD-exosomes. By integrating computational and preclinical evidence, our findings underscore the potential of exosome-based oral drug delivery systems in enhancing therapeutic efficacy.
Indexed as
Identifiers
40936044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.